micro-community-banner
 
  • Saved

6mo
GLP-1 Therapies in Metabolic and Hormonal Health: ENDO 2025 Insights

At ENDO 2025, Dr. Monica Laronda (Lurie Children’s Hospital, Northwestern University) highlighted emerging research investigating how GLP-1 therapies and rising obesity rates may influence puberty onset, menarche timing, and sex-specific disease expression—particularly in adolescents with high BMI or genetic susceptibility. She also discussed environmental and epigenetic drivers of endocrine disruption and underscored the need to consider sex as a biological variable in metabolic research. Dr. Shellsea Portillo (St. Louis University Hospital) presented retrospective data indicating that GLP-1–associated weight loss significantly improved testosterone levels in obese men with type 2 diabetes, suggesting a possible avenue for further exploration as a non-hormonal strategy for managing obesity-related hypogonadism. Together, these insights underscore GLP-1’s emerging but preliminary role in reproductive and metabolic endocrine health.

  • Saved

6mo
The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis - PubMed

The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39331324/

TSA analysis revealed sufficient data exist to confirm ExTr will improve all five lipid outcomes. CT is optimal for lipid management. The modest effect observed may moderate dyslipidemia medication for...

 

Exercise training modestly improves five key lipid markers, with combined training (aerobic + resistance) being most effective. Sufficient data confirm benefits, though responses vary, potentially influencing dyslipidemia management strategies.

  • Saved

6mo

I generally discuss the LDL goals for all pts with DM and prior MI and adjust the medications aggressively myself

  • Saved

6mo
Background Image DesktopBackground Image Mobile

In a phase 2b study, efruxifermin added to stable GLP-1RA therapy in MASH patients with T2D was safe and reduced hepatic fat fraction by 65% vs. 10% with GLP-1RA alone. It also improved noninvasive fibrosis and metabolic markers without impacting weight loss benefits.

Review the full trial findings here

  • Saved

6mo

Did you know? Statins are linked to a 9–12% increased risk of new-onset diabetes, particularly with long-term, high-dose use and in patients with impaired glucose regulation. Still, their cardiovascular benefits usually outweigh this risk, prompting continued use in most at-risk populations.

Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?

Statins

Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?